Medically Reviewed By
Dr. Aditya Singh, MBBS, MD (Pharmacology)
Reg No: MCI-654321 • Verified Medical Reviewer
Betmiga
(mirabegron)
Uses, side effects, dosage information & price range
About this medicine
Overactive bladder in adults Betmiga prolonged-release tablets are indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Neurogenic detrusor overactivity in the paediatric population Betmiga prolonged release tablets are indicated for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.
Common Brand Names for this Composition
The following popular commercial brand names contain mirabegron as their active ingredient composition:
Mirbeg 50 Tablet ER
Ipca Laboratories Ltd
Bladmir 25 Tablet ER
Alembic Pharmaceuticals Ltd
Betmiga
Astellas Pharma Europe B.V.
Common Substitutes & Alternatives
These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.
Key Information
Salt / Composition
mirabegron
Category
Urologicals
Manufacturer
Astellas Pharma Europe B.V.
Medical Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.
Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.